Skip to Content

Prelude Therapeutics Inc Ordinary Shares PRLD

Morningstar Rating
$5.16 −0.10 (1.90%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PRLD is trading at a 344% premium.
Price
$5.20
Fair Value
$89.28
Uncertainty
Extreme
1-Star Price
$93.59
5-Star Price
$1.76
Economic Moat
Nbysk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PRLD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.26
Day Range
$4.735.26
52-Week Range
$1.666.72
Bid/Ask
$5.16 / $6.60
Market Cap
$283.44 Mil
Volume/Avg
357,823 / 77,521

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
128

Comparables

Valuation

Metric
PRLD
CLDX
CELC
Price/Earnings (Normalized)
Price/Book Value
1.342.893.98
Price/Sales
310.95
Price/Cash Flow
Price/Earnings
PRLD
CLDX
CELC

Financial Strength

Metric
PRLD
CLDX
CELC
Quick Ratio
11.4431.4410.64
Current Ratio
11.6431.7711.23
Interest Coverage
−13.89
Quick Ratio
PRLD
CLDX
CELC

Profitability

Metric
PRLD
CLDX
CELC
Return on Assets (Normalized)
−39.87%−23.59%−40.23%
Return on Equity (Normalized)
−44.79%−25.21%−56.35%
Return on Invested Capital (Normalized)
−43.35%−25.04%−44.81%
Return on Assets
PRLD
CLDX
CELC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QxjzplpdsGwxj$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
RkbrgpqvNfzryzx$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
NzwhdtvggQmrngn$117.2 Bil
Moderna Inc
MRNA
NhhptmkSrbrf$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
HsdlhkbtgHwtyhbr$30.1 Bil
argenx SE ADR
ARGX
ZnqwlfvtMqbxn$28.0 Bil
BioNTech SE ADR
BNTX
FgkbxdnssNsp$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
LwswsbnlMqplf$16.0 Bil
United Therapeutics Corp
UTHR
VftrnbmqNqd$14.6 Bil
Incyte Corp
INCY
GfjbkvtdNnxzqj$13.0 Bil

Sponsor Center